Purple Book product · Interchangeable
Wezlana
ustekinumab-auub
Oct 31, 2023
Approved
Interchangeable
License type
Rx
Marketing
12
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Oct 31, 2023
2 yr 9 mo ago
First interchangeable exclusivity ends
Window blocking subsequent interchangeable approvals for the reference product.
Apr 30, 2025
1 yr 3 mo ago
Today
Pharmaceutical detail
Strength
130MG/26ML (5MG/ML)
Dosage form
Injection
Route
Intravenous
Presentation
Single-Dose Vial
Center
CDER
License number
1080
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Reference product family
View full familyBiosimilar of ustekinumab (Stelara)
Patent list (12)
| Patent | Expires | In | Source |
|---|---|---|---|
| 6,902,734 | Sep 25, 2023 | 2 yr 10 mo ago | FDA |
| 6,902,734 | Sep 25, 2023 | 2 yr 10 mo ago | FDA |
| 8,852,889 | Jul 06, 2032 | in 6 yr 1 mo | FDA |
| 8,852,889 | Jul 06, 2032 | in 6 yr 1 mo | FDA |
| 9,475,858 | Jul 06, 2032 | in 6 yr 1 mo | FDA |
| 9,475,858 | Jul 06, 2032 | in 6 yr 1 mo | FDA |
| 9,217,168 | Mar 14, 2033 | in 6 yr 9 mo | FDA |
| 9,217,168 | Mar 14, 2033 | in 6 yr 9 mo | FDA |
| 9,663,810 | Mar 14, 2033 | in 6 yr 9 mo | FDA |
| 9,663,810 | Mar 14, 2033 | in 6 yr 9 mo | FDA |
| 10,961,307 | Sep 24, 2039 | in 13 yr 5 mo | FDA |
| 10,961,307 | Sep 24, 2039 | in 13 yr 5 mo | FDA |
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
When do Wezlana's patents expire?
The FDA Purple Book lists 12 published patents for Wezlana, with the last listed patent expiring Sep 24, 2039. Every patent below links to its FDA source record so you can verify the expiration date.
Is Wezlana a biosimilar?
Yes. Wezlana is a Interchangeable referencing ustekinumab, licensed under a 351(k) BLA.
Is Wezlana interchangeable?
Yes. Wezlana carries an FDA interchangeability designation, so it may be substituted for the reference product at the pharmacy without prescriber involvement, subject to state law.
What is Wezlana's BLA number?
Wezlana is licensed under BLA 761331, held by Amgen Inc..
When was Wezlana approved by the FDA?
Wezlana was approved by the FDA on Oct 31, 2023.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
